| Bioactivity | ABAI-30 is a potent and orally active anti-inflammatory agent. ABAI-30 effectively inhibits NO production in lipopolysaccharide (LPS) induced RAW264.7 cells[1]. |
| Invitro | In RAW264.7 cells, ABAI-30 (10-40 μM) inhibits the TLR4-pp65 and NLRP3-caspase-1 signaling pathway, thus leading to the downregulation of IL6, IL-1β and TNFα at both transcriptional and translational levels[1]. |
| In Vivo | In a dextran sulfate sodium (DSS)-induced colitis mouse model, ABAI-30 (25 mg/kg; oral administration; for 5 days) demonstrates high in vivo anti-inflammatory efficacy without causing obvious toxicity[1]. |
| Name | ABAI-30 |
| CAS | 2757957-25-6 |
| Formula | C17H13N7O2 |
| Molar Mass | 347.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ling Li, et al. Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD). Bioorg Chem. 2022 Jan 20;120:105619. |